FOR PATIENTS LIKE…

Diagnosed with migraine 2 years ago.

Symptoms: Increased headache intensity and duration over the last year.

Considerations: Marnie has been self-managing her headaches with OTC medications.

Diagnosed with migraines 6 years ago.

Symptoms: Moderate to severe throbbing pain about once a week.

Considerations: Jennifer has expressed tolerability concerns relating to medication.

separator

FOR PATIENTS LIKE…

Diagnosed with migraine 2 years ago.

Symptoms: Increased headache intensity and duration over the last year.

Considerations: Marnie has been self-managing her headaches with OTC medications.

Diagnosed with migraines 6 years ago.

Symptoms: Moderate to severe throbbing pain about once a week.

Considerations: Jennifer has expressed tolerability concerns relating to medication.

separator

FOR PATIENTS LIKE…

Diagnosed with migraine 2 years ago.

Symptoms: Increased headache intensity and duration over the last year.

Considerations: Marnie has been self-managing her headaches with OTC medications.

Diagnosed with migraines 6 years ago.

Symptoms: Moderate to severe throbbing pain about once a week.

Considerations: Jennifer has expressed tolerability concerns relating to medication.

separator

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications with concomitant use of strong CYP3A4 inhibitors.

Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

 

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications with concomitant use of strong CYP3A4 inhibitors.

Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

 

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications with concomitant use of strong CYP3A4 inhibitors.

Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

 

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at
1-844-241-5011

*Fictitious case. May not be representative of general population.

*Fictitious case. May not be representative of general population.

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

© 2024 AbbVie. All rights reserved. 

CA-UBR-230004A / JN24  

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

© 2024 AbbVie. All rights reserved. 

CA-UBR-230004A / JN24